Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
Open accessPublished version of a preprint
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
A notable number of acute lymphoblastic leukemia (ALL) patients develop CD19-positive relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It remains unclear if the long-term response is associated with the characteristics of CAR T cells in infusion products, hindering the identification of biomarkers to predict therapeutic outcomes. Here, we present 101,326 single-cell transcriptomes and surface protein landscape from the infusion products of 12 ALL patients. We observed substantial heterogeneity in the antigen-specific activation states, among which a deficiency of T helper 2 function was associated with CD19-positive relapse compared with durable responders (remission, >54 months). Proteomic data revealed that the frequency of early memory T cells, rather than activation or coinhibitory signatures, could distinguish the relapse. These findings were corroborated by independent functional profiling of 49 patients, and an integrative model was developed to predict the response. Our data unveil the molecular mechanisms that may inform strategies to boost specific T cell function to maintain long-term remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This analysis led to discovery of TH2 cell pathways and related genes as potential targets for maintaining 5-year remission following CAR T cell immunotherapy.”
From The technological landscape and applications of single-cell multi-omics (2023) · cites this paper as [166]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lack of TH2 functionality might be the cause of relapse in CAR-T treatment.”
From Single-cell sequencing to multi-omics: technologies and applications (2024) · cites this paper as [209]
In the citing paper
“Single-cell multi-omics has also been applied to assess chimeric antigen receptor (CAR) T cell therapy in acute lymphoblastic leukaemia, combining transcriptomics and proteomics data to determine the molecular basis of phenotypic differences between complete remission, non-responsive and relapsed individuals166.”
From The technological landscape and applications of single-cell multi-omics (2023) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174 · cited 3×
“All differential expression analyses were performed using Seurat v3 (48).”
MethodInfluentialUMAP: Uniform Manifold Approximation and Projection
McInnes, L., Healy, J., Saul, N., & Großberger, L. (2018) · Journal of Open Source Software · doi:10.21105/joss.00861 · Cited by 9,826
Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets.
Macosko, E. Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, A. R., Kamitaki, N., Martersteck, E. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.002 · Cited by 7,110
UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction
McInnes, L., Healy, J., & Melville, J. (2018) · arXiv · doi:10.48550/arxiv.1802.03426 · Cited by 7,101 · cited 1×
“We used 20 canonical correlation analysis (CCA) dimensions and the default number of anchor neighbors and reduced the integrated mRNA data to two dimensions using UMAP for visualization (46).”
MethodScenic: single-cell regulatory network inference and clustering.
Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.-C., Geurts, P., Aerts, J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4463 · Cited by 6,520
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationCausal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citation
Research works printed but not linked: 1
- S. Schuster, M. R. Bishop, C. S. Tam, E. K. Waller, P. Borchmann, J. P. McGuirk, U. Jaeger, S. Jaglowski, C. Andreadis, J. R. Westin, I. Fleury, V. Bachanova, S. R. Foley, P. J. Ho, S. Mielke, J. M. Magenau, H. Holte, K. Van Besien, M. J. Kersten, T. Teshima, K. Tobinai, P. Corradini, O. Anak, L. B. Pacaud, C. del Corral, D. Pharma, R. Awasthi, F. Tai, G. Salles, R. T. Maziarz, Primary analysis of Juliet: A global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 130, 577 (2017).
Cited by
Items 101–178 of 178
A Proteomics Outlook on the Molecular Effectors of CAR-T Cell Therapy in Cancer Management
Teibo, J. O., Picanço‐Castro, V., de Souza, L. E. B., & Faça, V. M. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00930 · Cited by 7
A yeast surface display platform for characterizing CAR T cell responses to cancer antigens
Deichmann, M., Schiesaro, G., Ramanathan, K., Zeeberg, K., Koefoed, N. M. T., Ormhøj, M., Friis, R. U. W., Gill, R. T., Hadrup, S. R., Jensen, E. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65236-7 · Cited by 7
Development of optimized cytotoxicity assays for assessing the antitumor potential of CAR-T cells
Norbert, M. E., Cuffel, A., Riou, G., Jean, L., Blondel, C., Déhayes, J., Bisson, A., Giverne, C., Brotin, É., Denoyelle, C., et al. (2023) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113603 · Cited by 7
Loeffler‐Wirth, H., Rade, M., Arakelyan, A., Kreuz, M., Loeffler, M., Koehl, U., Reiche, K., & Binder, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.994885 · Cited by 8
“derived from (13) or (50)], to disentangle cellular identities and transcriptional states of bulk samples, and to extend the analyses presented here by future studies in terms of additional patient samples and longitudinal measurements.”
BackgroundSingle-cell technologies uncover intra-tumor heterogeneity in childhood cancers
Lo, Y., Liu, Y., Kammersgaard, M. B., Koladiya, A., Keyes, T., & Davis, K. L. (2023) · Seminars in Immunopathology · doi:10.1007/s00281-022-00981-1 · Cited by 7
“patients, whereas other major immune programs remained unchanged [42].”
BackgroundLiao, Y., Hsu, S., & Chiou, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042416 · Cited by 7
“Bai et al., using an scRNA-seq analysis, discovered that a deficiency of TH2 function, as well as a lack of TH2 cytokine molecules such as IL-4, IL-5, and IL-13, were associated with CD19-positive relapse in patients [96] (Figure 2A).”
BackgroundMethodInfluentialThe Bidirectional Interplay between T Cell–Based Immunotherapies and the Tumor Microenvironment
Pherez-Farah, A., Boncompagni, G., Chudnovskiy, A., & Pasqual, G. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0857 · Cited by 6
“Surprisingly, a type 2 functional status of the infusion products was associated with sustained therapeutic responses (118, 119).”
The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies
Krawczyk, M., Drużyńska, M., Bednarska, E., & Winiarska, M. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189519 · Cited by 5
In vivo CAR-T therapy: from molecular design to precision delivery
Li, H., Wen, W., Zhao, X., & Liang, G. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04232-5 · Cited by 7
Nowicki, T. S., Peters, C. W., Quiros, C., Kidd, C. K., Kawakami, M., Klomhaus, A. M., Baselga-Carretero, I., Kaplan‐Lefko, P. J., Macabali, M. H., Garcilazo, I. P., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0577 · Cited by 5
CAR T-cells for acute leukemias in children: current status, challenges, and future directions
Dourthe, M.-É., & Baruchel, A. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10261-7 · Cited by 6
“A deficiency of T helper 2 function was associated with CD19-positive relapse [41].”
Ligon, J. A., Ramakrishna, S., Ceppi, F., Calkoen, F., Diorio, C. J., Davis, K. L., Jacoby, E., Gottschalk, S. M., Schultz, L. M., & Capitini, C. M. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.012 · Cited by 5
Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy
Lei, Y., Liu, N., Qin, D., Liu, M., & Wang, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02515-3 · Cited by 6
Driessen, A., Born, J., Castellanos-Rueda, R., Reddy, S. T., & Rapsomaniki, M. (2026) · Cell Systems · doi:10.1016/j.cels.2026.101591 · Cited by 4
George, S., & Johdi, N. A. (2025) · Current Molecular Medicine · doi:10.2174/0115665240355043250130110501 · Cited by 5
Single-cell technologies to dissect heterogenous immune cell therapy products
Mueller, K. P., & Saha, K. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100343 · Cited by 4
The race to supercharge cancer-fighting T cells
Ledford, H. K. (2023) · Nature · doi:10.1038/d41586-023-00177-z · Cited by 4
Schultz, L. M., & Mackall, C. L. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2227086 · Cited by 5
Single-cell genomics-based immune and disease monitoring in blood malignancies
Rathgeber, A. C., Ludwig, L. S., & Penter, L. (2024) · Clinical Hematology International · doi:10.46989/001c.117961 · Cited by 5
Multidimensional analysis reveals predictive markers for CAR-T efficacy
Letscher, K. P., & Reddy, S. T. (2024) · Nature Cancer · doi:10.1038/s43018-024-00785-2 · Cited by 4
Differentiated strategies for nanovaccines in lymphoma immunotherapy: advances and challenges
Xia, Y., Liang, T., Shang, W., Zhang, G., & Lu, Y. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00528k · Cited by 3
The T cell subsetting challenge
Comet, N. R., & Gerlach, C. (2025) · Trends in Immunology · doi:10.1016/j.it.2025.05.005 · Cited by 3
Insights into Leukemia from Single-Cell Genomics
Sariipek, N. E., & van Galen, P. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062024-060443 · Cited by 3
Wang, M., Zhu, L., Li, Y., Zhao, Y., Wang, M., Liao, J., Yuwen, Z., Liu, P., He, F., Han, X., et al. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c03452 · Cited by 2
Wang, G., Huang, M., Jiang, L., Zhang, X., Wang, Z. M., Yu, Q., Li, D., Yang, Y., Yang, X., & Cao, Y. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04001-7 · Cited by 2
Personalized Medicine, the Inevitable Future of Cancer Immunotherapy
Basiri, M. (2023) · Personalized Medicine · doi:10.2217/pme-2023-0083 · Cited by 2
Oszer, A., Pawlik, B., Ćwilichowska-Puślecka, N., Marschollek, P., Richert-Przygońska, M., Mielcarek‐Siedziuk, M., Crawford, J. C., Mazurek, M., Koladiya, A., Kałwak, K., et al. (2025) · Haematologica · doi:10.3324/haematol.2025.288397 · Cited by 1
Dreyzin, A., Gava, F. M., Lamplugh, C., Ma, J., & Silbert, S. K. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201171 · Cited by 4
“95,96 96–100 Conversely, elevated levels of regulatory T cells before CAR infusion have been linked to poor relapse-free survival (RFS).”
Ponatinib inhibits LCK and PI3K signaling and promotes CD8+ T stem cell memory cell development
Okuhiro, Y., Ito, S., Watanabe, K., Yan, Y., Kumagai, K., Sato, T., Kojima, Y., Fujioka, Y., Takahashi, N., Kiyoi, H., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71375-2 · Cited by 2
Liu, X., Wang, H.-N., Zeng, L., Liang, Y.-Z., Li, F.-L., Zhu, J.-Y., Cong, J., & Wang, L. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08394-6 · Cited by 1
“Single-cell profiling of CAR-T infusion products has further revealed that product composition, including T cell differentiation states and memory phenotypes, predicts relapse risk [7, 8].”
A distinct CAR-T cell phenotype mediates therapeutic response at limited doses
Yousefian, S., Schubert, M., Minafra, A. R., Derigs, P., Gräßle, S., Horne, A., Demel, U. M., Liebaert, J., Röthemeier, C., Pupp, F., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76068-4 · Cited by 2
Mai, Y., Wang, Z., Wang, J., Song, M., Xiang, T., He, Y., Chang, A. H., & Zhang, Y. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00822-z · Cited by 1
“[198–200].”
Adaptable Leukemia Cells Resisting CAR T-cell Attack via B-cell Activation
Zhao, Z., & Melenhorst, J. J. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0543 · Cited by 1
Self-citationYang, L., Wang, T., Guan, X., He, C., Shi, H., Wu, H., & Liao, X. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.10.648158 · Cited by 1
Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responsesPreprint
Pan, T., Tang, E., Hu, Y., Asby, N. W., Schubat, M., Althaus, T., Riedell, P. A., Derman, B. A., & Huang, J. (2025) · medRxiv · doi:10.1101/2025.07.10.25331322 · Cited by 1
“…are consistent with previous studies reporting that less activated, less differentiated infusion product phenotypes correlate with greater expansion, longer persistence, and overall more favorable therapeutic responses 17–19 , which is frequently mediated by IL-2, IL-7, and IL-15 17–19 , 52– 54 .”
Bouwers, E. G. (2011) · PUB – Publications at Bielefeld University (Bielefeld University)
Wilhelm, A. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.71494
Slavkovic‐Lukic, D., Fioravanti, J., Martín-Santos, A., Han, E., Zhou, J., & Gattinoni, L. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3593-3_11 · Cited by 1
Blache, U., Kebbel, K., Quaiser, A., Popp, G., Franz, P., Dünkel, A., Thoma, M., König, N., Platzbecker, U., Schmiedeknecht, G., et al. (2023) · Springer eBooks · doi:10.1007/978-3-662-67908-1_8
Alternative immune effector cells picking up speed
Weber, E. W., Bleakley, M., Cronk, J. C., Shah, N. N., & Perna, F. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.030
Analytical Tools to Quantitate Immune Mediated Effects
Pavelko, K. D., & Villasboas, J. C. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch26
Liu, M., Tan, K., Cao, H., Huang, S., Qian, C., Xue, S., Dai, H., & Gong, W. (2024) · HemaSphere · doi:10.1002/hem3.49
Lu, C., Xu, J., & Mei, H. (2024) · PubMed Central · doi:10.3760/cma.j.cn121090-20240701-00242
Parry, T. L., Gilmore, L. A., & Khamoui, A. V. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-024-01524-7
“…Marx 2021), CITE-seq for combined single cell RNA-seq and surface protein expression analysis to uncover cell type identities in blood disorders (Bai et al. 2022), ATAC-seq for chromatin accessibility (Rendeiro et al. 2020) or TCR-and BCR-seq to probe receptor repertoire diversity in T and B…”
Performing an In Vitro Genome-Wide CRISPR Knockout Screen in Chimeric Antigen Receptor T Cells
Stewart, C. M., Roman, C. M., & Kenderian, S. S. (2025) · Journal of Visualized Experiments · doi:10.3791/67338
Memory matters: T cell phenotype shapes CAR T cell fate
Meo, F. D. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.011
Improving Quality of CAR-T Cell Therapy Starting Material with Automated Microfluidic Cell SortingPreprint
Skelley, A. M., Behmardi, Y., Petersen, L., Shehada, M., Ouaguia, L., Gandhi, K., Campos‐González, R., & Ward, T. (2025) · medRxiv · doi:10.64898/2025.12.16.25342401
Schubert, M.-L., Schmitt, A., Hückelhoven‐Krauss, A., Neuber, B., Kunz, A., Waldhoff, P., Vonficht, D., Yousefian, S., Jopp‐Saile, L., Wang, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26606005
Development of a chimeric antigen receptor dendritic cell platform
Gordon, B. (2023) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/28504
Choi, S., Chiang, A. Y., Cheng, C., Dai, T., Yeh, T.-M., & Pikounis, B. (2026) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2026.2627384
U25 Fest. Ideas para crecer en comunidad. Memorias Científicas
Arenas-Díaz, G., Velásquez, J. N., Sarmiento, L. R., López, E. O., Opsina, R. O., Martín, A. Á., Plata, L. M. D., Suárez, C. I. S., Martínez, L. O. P., Ojeda, O. M. Á., et al. (2025) · Universidad Industrial de Santander
Oner, A., Nooteboom, N., Oosting, L. T., Kosterink, J. G. W., Dekkers, B. G. J., van der Graaf, A. C., van Meerten, T., Krenning, G., Swart, D. H., Dennebos, R., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040414
“Since CAR-T cell phenotypical subsets (e.g., Tn, Tcm) and exhaustion markers correlate with clinical outcomes [54–58], these were analyzed during the stability study to ensure no significant undesired changes occurred.”
Skelley, A. M., Behmardi, Y., Peterson, L. F., Inglis, D. W., Shehada, M., Ouaguia, L., Gandhi, K., Campos‐González, R., & Ward, T. (2026) · Lab on a Chip · doi:10.1039/d6lc00072j
Cappabianca, D., Toulany, M., Zima, S. R. T., Shea, A. G., Vidugirienė, J., Lauer, A. C., Sylvester, K., Gnanasekar, V., Foster, S., Turaga, R. V., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201200
Impaired hematopoiesis affects apheresis and CAR T‐cell product composition and treatment response
Kuhn, H., Korell, F., Hückelhoven‐Krauss, A., Neuber, B., Stenzinger, M., Ludwig‐Husemann, A., Schubert, M., Derigs, P., Farid, K. M. N., Sauer, T., et al. (2026) · Transfusion · doi:10.1111/trf.70224
“43 In pediatric patients with B-cell precursor ALL treated with tisa-cel, treatment response was linked to natural killer and monocyte phenotypes in the peripheral blood rather than CAR T-cell composition.”
Endogenous CD28 takes the driver’s seat in 4-1BB co-stimulated CAR T cells
Tong, J. H., & Olejniczak, S. H. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201192
“5 Similarly, patients with decade-long remissions following BB ζ CAR T cell therapy contained circulating CD4 + BB ζ CAR T cells exhibiting high CD28 expression that were viewed as critical for maintaining durable tumor control.”
Shih, Y.-P., Drokin, S., Burke, O., Huang, H., Leung, A., Bravo-Manríquez, M., Jang, M., Syrkina, M. S., Julian, L., Sanjuan, N., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1847411
(18883), Q. C., Sedloev, D. N., Yao, H., Mao, L., Depke, D. A., Wang, L., Scheller, M., He, B., (36759), Y. L., Unglaub, J. M., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.027
A soluble bi-specific fusion protein for the improved expansion of human CD8 + CAR-T cellsPreprint
Law, J. C., Matus, E. I., Mina, P. R., Sparkes, A., Asokumar, N., Trottier, S., Kim, G. B., & Gariépy, J. (2026) · medRxiv · doi:10.64898/2026.06.16.26355813
CAR T cell foundation model predicts immunotherapy responsePreprint
Li, Y., Fang, D., Mao, C., Wu, X., & Luo, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.11.737994
Single-cell foundation models predict durable CAR T response despite imperfect cell annotationPreprint
Shen, L., Bai, Z., Yang, M., Li, N., & Fan, R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.22.740224
Self-citationMicrobial Metabolites Potentiate MAIT Cell Anti-Tumor Immunity Against Solid TumorsPreprint
Zhu, Y., Shen, X., Chen, Y., Ma, N., Zhang, C., Zhao, A., Tian, Y., Gumate, S., Huang, J., Lin, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.24.740456
Single-cell foundation models predict durable CAR T response despite imperfect cell annotationPreprint
Fan, R., Shen, L., Bai, Z., Yang, M., & Li, N. (2026) · Research Square · doi:10.21203/rs.3.rs-10412263/v1
Self-citationHypoxia during GPC2-CAR T-cell manufacturing compromises cell expansion and cytotoxic capacity
Phadke, I., Hannon, R. A., Black, M., Schmiechen, Z. C., Song, H. W., Lei, H., Shern, J. F., Prochazkova, M., Oh, J., Ho, M., et al. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102980
Kim, D., Park, J., Kang, M.-S., & Jung, H.-W. (2026) · Interdisciplinary Research in Medical Sciences Specialty · doi:10.51847/sliihvvjvi
Self-citationMoser, L. M., Hutter, M., Ahlmann, M., Alonso‐Saladrigues, A., Attarbaschi, A., Ayuk, F. A., Baldus, C. D., Balduzzi, A., Bonig, H. B., Bourquin, J., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03105-y
Endothelin receptor blockade potentiates adoptive T cell and CAR T cell therapiesPreprint
Papagregoriou, C., Mpekris, F., Yoon, J., Kastrappis, G., Lytridou, A. A., Thrasyvoulou, M., Symeonidis, K., Pitsillidou, C., Neophytou, C., Panagi, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.02.748239
Microbial Metabolites Potentiate MAIT Cell Anti-Tumor Immunity Against Solid TumorsPreprint
Zhu, Y., Shen, X., Chen, Y., Ma, N., Zhang, C., Zhao, A., Tian, Y., Gumate, S., Huang, J., Lin, S., et al. (2026) · eLife · doi:10.7554/elife.112587
Ferreira, M. R. (2026) · eLife · doi:10.7554/elife.112587.1.sa3
Microbial Metabolites Potentiate MAIT Cell Anti-Tumor Immunity Against Solid TumorsPreprint
Zhu, Y., Shen, X., Chen, Y., Ma, N., Zhang, C., Zhao, A., Tian, Y., Gumate, S., Huang, J., Lin, S., et al. (2026) · eLife · doi:10.7554/elife.112587.1
Yao, Y., Yan, F., Li, X., Li, Y., Fei, Y., McIntosh, J. M., Wang, W., Lee, H., Liu, Y., & Wang, M. L. (2026) · Leukemia · doi:10.1038/s41375-026-03146-3
Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death
Levchuk, K., Petukhov, A., Tursymbek, S., Seitkamal, K., Bertleuova, A., Bulanin, D., & Barlev, N. A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1963794
“Another single-cell study linked early-memory and type-2 functional features, rather than activation or coinhibitory marker expression alone, to durable remission (138).”
Martelli, J. (2026) · Journal of Genetic Engineering and Biotechnology Research · doi:10.33140/jgebr.08.03.02
Park, S., Cho, H. J., Song, Y., Kim, J. H., Tian, C., Baek, C., Hyung, S., Shin, Y. J., Yoon, S. E., & Cho, S. (2026) · ACS Sensors · doi:10.1021/acssensors.6c03294
Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion
Bai, Y., Qin, J., Dai, Z., Yan, R., Yang, Y., & Wang, W. (2026) · Exploration · doi:10.1002/exp2.70230
Budka, J. A., Davis, M. J., Cao, S., Ding, J., Margaitis, J., Zhang, W., Winters, J., Vardhanabhuti, S., Arihara, Y., Williams, C. M., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04707-w
Self-citationHanna, E. A., Amitrano, A., Forjaz, A., Bai, Z., Min, C., Dance, Y. W., Etoh, I., Lloyd, B., Jiang, X., Queiroga, V., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.22.760671
“This condition aligned with transcriptional clusters enriched for memory signatures, consistent with prior reports linking memory-associated phenotypes with durable responses in some patients 38–40 .”
Self-citation
Metadata
- Authors
- Bai, Z., Woodhouse, S., Zhao, Z., Arya, R., Govek, K., Kim, D., Lundh, S., Baysoy, A., Sun, H., Deng, Y., Xiao, Y., Barrett, D. M., Myers, R. M., Grupp, S. A., June, C. H., Fan, R., Camara, P. G., & Melenhorst, J. J.
- Affiliations
- Yale University (US)
- University of Pennsylvania (US)
- Cleveland Clinic (US)
- Children's Hospital of Philadelphia (US)
- Parker Institute for Cancer Immunotherapy (US)
- Yale Cancer Center (US)
- Department of Genetics and Institute for Biomedical Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Corresponding author
- Bai, Zhiliang
- Woodhouse, Steven
- Fan, Rong
- Melenhorst, J. Joseph
- ORCID
- Venue
- Science Advances
- Published
- 2022-06-10
- Volume
- 8
- Issue
- 23
- Pages
- eabj2820-eabj2820
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC9177075
- OpenAlex
- W4281666488
- Cited by
- 166
- References
- 50
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 36 · 2023: 36 · 2022: 13
- FWCI
- 14.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nd)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Yale University
- Entertainment Industry Foundation
- Li Ka Shing Foundation
- Society for Immunotherapy of Cancer
- Stand Up To Cancer
- National Cancer Institute (U01CA232361)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- acute lymphoblastic leukemia, CAR T-cell therapy, CD19, relapse, single-cell transcriptomics, T cell heterogeneity, co-inhibitory receptors, response prediction, biomarkers, T cell activation
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Recurrence, Immunotherapy, Adoptive, Antigens, CD19, Proteomics, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.